GlassScriptPhysician profile
Addi Suleiman
NPI 1518262088
$8,666.72
in general payments reported to CMS, 2019-2025
27 companies · $521 in 2025
The $521 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,773 · 2020: $569 · 2021: $886 · 2022: $633 · 2023: $643 · 2024: $641 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,252.62 | 2019-2025 | Mitraclip, Emboshield Nav6 |
| Medtronic Vascular, INC. | $1,619.03 | 2019-2020 | |
| Medtronic, INC. | $1,043.84 | 2021-2025 | Corevalve Evolut R |
| Edwards Lifesciences Corporation | $732.92 | 2019-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $366.82 | 2019-2024 | |
| Abiomed | $359.08 | 2019-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $246.13 | 2020-2024 | Lifevest |
| Glaxosmithkline, LLC. | $120.57 | 2022-2024 | Arexvy |
| Philips North America LLC | $115.55 | 2020-2022 | |
| Amgen INC. | $113.50 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.96 | 2023 | Jardiance |
| Boston Scientific Corporation | $69.91 | 2019-2022 | |
| Cook Medical LLC | $58.03 | 2019-2020 | |
| Atricure, INC. | $53.96 | 2023 | |
| Shockwave Medical, INC | $50.98 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $48.50 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $43.44 | 2019-2020 | |
| Cardiovascular Systems INC. | $42.22 | 2021-2022 | |
| Pfizer INC. | $41.97 | 2019-2024 | |
| Acist Medical Systems, INC. | $30.07 | 2023 | |
| Novo Nordisk INC | $28.50 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $27.39 | 2021 | |
| Baxter Healthcare | $26.88 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| E.R. Squibb & Sons, L.L.C. | $25.43 | 2021-2022 | |
| Cvrx, INC. | $22.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $12.46 | 2022 | |
| Dexcom, INC. | $12.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Addi Suleiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.